Add like
Add dislike
Add to saved papers

Radiotherapy Outcome for Pediatric Pelvic Ewing Sarcoma.

OBJECTIVE: To evaluate the outcomes of patients undergoing radiotherapy for primary local control of pelvic ewing sarcoma (ES).

STUDY DESIGN: Case series.

PLACE AND DURATION OF STUDY: Shaukat Khanum Memorial Cancer Hospital, Lahore, from January 2010 to October 2015.

METHODOLOGY: Patients with primary pelvic ES were included in the analysis and all other primary disease sites were excluded. All of them were treated with radiotherapy and followed the EuroEwing-99 chemotherapy protocol. Tumor volume, relapse and metastases were noted.

RESULTS: There were 13 patients with pelvic ES. The median age at the time of diagnosis was 15 years with IQR of 7 years (range 2-19 years). Tumor volume was more than 400ml in more than 50% of the patients. Eight patients (61.5%) had local relapses and 5 patients (38.5%) had combined local and distant disease metastases.

CONCLUSION: These results showed poor local control and overall survival in local pelvic ES cases in children and adolescents. Intensity modulated radiotherapy (IMRT) can be used to deliver higher doses of radiation. Compressed cycles of chemotherapy should be evaluated in local setting.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app